Author/Authors :
Shahpouri, Mohammad Mehdi Department of Neurology - School of Medicine - Isfahan University of Medical Sciences, Isfahan, Iran , Mousavi, Ali Isfahan Neurosciences Research Center, Isfahan, Iran , Khorvash, Faribourz Isfahan Neurosciences Research Center, Isfahan, Iran , Mousavi, Morteza Isfahan Neurosciences Research Center, Isfahan, Iran , Hoseini, Tahereh Isfahan Neurosciences Research Center, Isfahan, Iran
Abstract :
For many years, anticoagulants have been used in the emergent treatment of patients with acute ischemic stroke. Anticoagulants are
prescribed in an effort to prevent first or recurrent stroke, especially among patients with cardioembolism due to arterial fibrillation
and large-artery atherosclerotic disease. Despite the widespread use, efficacy and safety of anticoagulants are controversial. Experts
have given a broad spectrum of opinions. Surveys of practitioners have also demonstrated a lack of consensus on the use of anticoagulants
for ischemic stroke. The uncertainty is due, in large part, to the lack of definitive clinical data. A review by the panel of the
Stroke Council of the American Heart Association found no strong evidence for effectiveness of anticoagulants in treating acute
ischemic stroke. Several clinical trials have suggested that utility of emergent anticoagulation has no significant effect in improving
clinical outcomes for patients with acute ischemic stroke. In the present review, we have attempted to provide a framework for the
emergent use of anticoagulants in acute ischemic stroke patients.